PRIMARY OBJECTIVE:
I. To determine the safety and feasibility of cryoablation of a primary breast tumor followed by PD-L1 blockade in patients with locally advanced or metastatic triple negative breast cancer (TNBC).
SCONDARY OBJECTIVE:
I. To evaluate the systemic immune response to cryoablation of a primary breast tumor and PD-L1 blockade.
OUTLINEPatients undergo cryoablation of the primary tumor over about 1 hour. After 2-3 weeks, patients receive atezolizumab intravenously (IV) on days 1 and 15 and nab-paclitaxel IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 2-3 weeks post surgery and then periodically thereafter.
